Dermatology

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases

Retrieved on: 
Thursday, March 30, 2023
Hives, Galderma, Thibaud, Coronavirus Scientific Advisory Board, Toxicity, B cell, Doctor of Philosophy, Biology, Knowledge, POC, Therapy, IND, Safety, Management, Pharmaceutical industry, Vaccine, Dermatology, Granularity

LONDON, March 30, 2023 /PRNewswire/ --  Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies., Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development.

Key Points: 
  • This approach can drive direct and specific mast cell inhibition, avoid systemic toxicity and enable safe chronic dosing for mast cell driven diseases such as chronic urticaria or systemic mastocytosis.
  • Brian Kim, Scientific Advisory Board member of Granular Therapeutics, remarked: "Recent data in the field of mast cell driven diseases like Urticaria have shown that tremendous efficacy can be attained, but safety concerns still remain, especially in chronic disease settings.
  • As Granular embarks on the development of its mast cell targeting pipeline of therapies towards clinical phases, it has appointed a dermatology expert, Dr Thibaud Portal, as Chief Executive Officer.
  • Selective mast cell targeting offers outstanding opportunities to address a range of disease indications with a high unmet medical need.

Granular Therapeutics to accelerate development of next-generation pipeline for treating mast cell driven diseases

Retrieved on: 
Thursday, March 30, 2023
Hives, Galderma, Thibaud, Coronavirus Scientific Advisory Board, Toxicity, B cell, Doctor of Philosophy, Biology, Knowledge, POC, Therapy, IND, Safety, Management, Pharmaceutical industry, Vaccine, Dermatology, Granularity

LONDON, March 30, 2023 /PRNewswire/ --  Granular Therapeutics, (Granular) a private biotech company specialising in precision biologic therapies for treating mast cell driven disorders, today announces clinical candidate selection for its lead programme which has demonstrated promising results in initial preclinical studies., Granular has now commenced proof-of-concept (POC) and IND-enabling studies as it prepares for clinical development.

Key Points: 
  • This approach can drive direct and specific mast cell inhibition, avoid systemic toxicity and enable safe chronic dosing for mast cell driven diseases such as chronic urticaria or systemic mastocytosis.
  • Brian Kim, Scientific Advisory Board member of Granular Therapeutics, remarked: "Recent data in the field of mast cell driven diseases like Urticaria have shown that tremendous efficacy can be attained, but safety concerns still remain, especially in chronic disease settings.
  • As Granular embarks on the development of its mast cell targeting pipeline of therapies towards clinical phases, it has appointed a dermatology expert, Dr Thibaud Portal, as Chief Executive Officer.
  • Selective mast cell targeting offers outstanding opportunities to address a range of disease indications with a high unmet medical need.

SkinCure Oncology Elevates Steven Scott and Joshua Swindle to Senior Executive Slots

Retrieved on: 
Wednesday, March 29, 2023
Gaar, Scott & Co., Health administration, Mohs surgery, Radiation, Master of Health Administration, Dermatology, Cancer, Varian Medical Systems, American Registry for Diagnostic Medical Sonography, Forbes School of Business & Technology, American Society of Radiologic Technologists, Radiographer, Patient, HCA, Texas State University, National Directorate for Migration (Argentina), Chief innovation officer, Society, MD Anderson Cancer Center, Management, Medical imaging, Science, Radiation therapy, Central Texas, Mohs, Swindle

Steven L. Scott, formerly the company's Chief Operations Officer, has been named Chief Strategy & Innovation Officer and Executive Vice President, and Joshua Swindle, who previously served as National Director of Practice Operations, is the company's new Chief Operating Officer.

Key Points: 
  • Steven L. Scott, formerly the company's Chief Operations Officer, has been named Chief Strategy & Innovation Officer and Executive Vice President, and Joshua Swindle, who previously served as National Director of Practice Operations, is the company's new Chief Operating Officer.
  • Scott co-founded the company in 2016 with Chief Executive Officer Kerwin Brandt after a long career in healthcare and business management.
  • "I'd known and admired Steven Scott for many years when we launched SkinCure Oncology to meet the needs of the 3.5 million Americans who are diagnosed with nonmelanoma skin cancer each year.
  • Josh's talent for prioritizing and addressing customer, employee and organizational issues with calm efficiency will go a long way toward helping SkinCure Oncology fulfill its corporate objectives."

DefenAge® 150K Hair Follicle Serum Won the "Best Hair Growth Serum" Award Presented by NewBeauty Magazine

Retrieved on: 
Wednesday, March 29, 2023
Human serum albumin, Hair, Surgeon, Telogen effluvium, Doctor of Philosophy, Hair loss, Serum, Menopause, Light, Woman, Scalp, Dermatology, Collection, Physician, Defensin, Cosmetics, Wool, Pregnancy

CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- DefenAge®, the manufacturer and distributor of the revolutionary, evidence-based, anti-aging products, is proud to announce that its new 150K Hair Follicle Serum is a 2023 NewBeauty Award Winner for "Best Hair Growth Serum."

Key Points: 
  • CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- DefenAge® , the manufacturer and distributor of the revolutionary, evidence-based, anti-aging products, is proud to announce that its new 150K Hair Follicle Serum is a 2023 NewBeauty Award Winner for " Best Hair Growth Serum ."
  • Made for both men and women, the DefenAge 150K Hair Follicle Serum utilizes the brand's patented, regenerative Defensins to target all 150,000 hair follicles on the scalp for less shedding and optimal hair growth.
  • The 150K Hair Follicle Serum delivers results proven in state-of-the-art research.
  • Hair loss physicians and hair transplant surgeons also recommend using the 150K Hair Follicle Serum as an outstanding supplement to hair restoration procedures and treatments.

SciBase and Schweiger Dermatology Group partner to advance skin cancer detection in select New Jersey locations

Retrieved on: 
Wednesday, March 29, 2023
Skin, Partnership, Dermatology, Skin cancer, Melanoma, Patient, FDA, Medical imaging, Freehold

Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.

Key Points: 
  • Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.
  • The agreement will provide Schweiger Dermatology Group's Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.
  • In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group's Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology.
  • For SciBase, we establish a further partner that helps introduce Nevisense to US payers," said Simon Grant, Chief Executive Officer of SciBase.

SciBase and Schweiger Dermatology Group partner to advance skin cancer detection in select New Jersey locations

Retrieved on: 
Wednesday, March 29, 2023
Skin, Partnership, Dermatology, Skin cancer, Melanoma, Patient, FDA, Medical imaging, Freehold

Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.

Key Points: 
  • Schweiger Dermatology Group is the largest dermatology practice group in the Northeastern US, with over 90 offices and more than 300 healthcare providers throughout New York, New Jersey, Pennsylvania and Connecticut.
  • The agreement will provide Schweiger Dermatology Group's Freehold, New Jersey practice with Nevisense, the only FDA approved test for early melanoma detection at point-of-care.
  • In addition to the early detection benefits for patients, the partnership means clinicians at Schweiger Dermatology Group's Freehold and Verona, New Jersey offices will have access to state-of-the-art melanoma detection technology.
  • For SciBase, we establish a further partner that helps introduce Nevisense to US payers," said Simon Grant, Chief Executive Officer of SciBase.

PharmaForce International: Key US Immunology-Focused Organizations Expanded into the Respiratory Space in 2022

Retrieved on: 
Tuesday, March 28, 2023
PFI, Asthma, Marketing, Dermatology, Intelligence, Multimedia, Organization, Patient, Immunology, Small Business Saturday, Benchmarking, Caregiver, Medical device, Gastroenterology

This report focused on the key companies with products competing across the Dermatology, Gastroenterology, and Rheumatology markets throughout 2022.

Key Points: 
  • This report focused on the key companies with products competing across the Dermatology, Gastroenterology, and Rheumatology markets throughout 2022.
  • In addition to those three therapeutic areas of focus, the Respiratory space has also become a key area of interest.
  • Many profiled companies have started to promote Respiratory products under their Immunology divisions.
  • "The respiratory focused products have definitely given way for the Immunology space to expand both with products and field deployed personnel.

Zero Gravity Devices Are Now Available at The Dermatology Office of Dr. Ellen Turner

Retrieved on: 
Tuesday, March 28, 2023
Dallas, Oxygen, Elastin, Dermatology, Sapphire, Ageing, Nutrient, ThinkPad X series, Cell, Inflammation, Pigment, Capillary, LED, Oxidative stress, Beauty, GENESIS, NASA, Lifting, Collagen, Woman, Red, Skin, Cosmetics

Starting this spring, board-certified dermatologist Dr. Ellen Turner is offering a range of cosmetic treatments from Zero Gravity: Perfectio X™, Sapphire X™, Genesis Z, GENESIS PRIME, and Aecor Max.

Key Points: 
  • Starting this spring, board-certified dermatologist Dr. Ellen Turner is offering a range of cosmetic treatments from Zero Gravity: Perfectio X™, Sapphire X™, Genesis Z, GENESIS PRIME, and Aecor Max.
  • The technology powering these devices helps to reverse damage to skin cells and deliver stunning results.
  • The X Series by Zero Gravity consists of treatments like Perfectio X™ and Sapphire X™.
  • Sapphire X™ is a blue light phototherapy device that reduces blemishes, detoxifies, and addresses inflammation, redness, and scars for a clearer, more even complexion.

Skincare Industry Pioneers Hydrinity and Wings Loveliness Collaborate to Launch New Revolutionary Professional Skincare Products into Europe

Retrieved on: 
Monday, March 27, 2023
Regenerative medicine, Hyaluronic acid, Dermatology, Partnership, Skin, Pharmaceutical industry

This strategic alliance will enable Hydrinity to expand its market presence into Europe.

Key Points: 
  • This strategic alliance will enable Hydrinity to expand its market presence into Europe.
  • "We are thrilled to partner with Wings Loveliness, a company that shares our passion for cutting-edge skincare solutions," says Keith O'Briant, CEO of Hydrinity.
  • "We believe that the collaboration between Wings Loveliness and Hydrinity will bring a new level of innovation and excellence to the European skincare market," says Baczyńska.
  • With this partnership, Hydrinity and Wings Loveliness aims to redefine the standards of skincare in Europe, leveraging their combined expertise to deliver revolutionary products to a broader audience.

For the 5th year straight, ModMed® voted #1 for Integrated Practice Management, Revenue Cycle Management and EHR

Retrieved on: 
Tuesday, March 28, 2023
Software, Practice Management, General Health, Health, Data Management, Hospitals, Health Technology, Technology, ENT, Podiatry, Surgeon, PM, Gastroenterology, Workflow, Surgery, VBC, RCM, Multimedia, Dermatology, Revenue cycle management, Patient, EHR, Ophthalmology, Pain management, Electronic health record, Black Book, Urology, Nursing

Specialty-specific healthcare technology leader ModMed® today announced its #1 ranking by Black Book™ Research for the fifth year in a row for Integrated Practice Management, Revenue Cycle Management and Electronic Health Record (EHR) in Surgical Specialties.

Key Points: 
  • Specialty-specific healthcare technology leader ModMed® today announced its #1 ranking by Black Book™ Research for the fifth year in a row for Integrated Practice Management, Revenue Cycle Management and Electronic Health Record (EHR) in Surgical Specialties.
  • View the full release here: https://www.businesswire.com/news/home/20230328005340/en/
    For the 5th year straight, ModMed® voted #1 for Integrated Practice Management, Revenue Cycle Management and EHR (Graphic: Business Wire)
    "ModMed continues to be the top choice for surgeons, with proven solutions that are specialty-specific and integrated functionality that surgical practices need," said Doug Brown, Managing Partner of Black Book.
  • These products and services are part of a fully integrated suite of solutions to help address the clinical, operational, and financial aspects of specialty practices.
  • Staff Coordinator Rachel Harrison, of Brevard Medical Dermatology, shared, “Once our office started using the PM system, our workflow completely improved.